DUOPHARMA BIOTECH BERHAD
KLSE (MYR): DPHARMA (7148)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
1.37
Today's Change
-0.02 (1.44%)
Day's Change
1.36 - 1.40
Trading Volume
396,600
Overview
Market Cap
1,318 Million
NOSH
960 Million
Avg Volume (4 weeks)
560,750
4 Weeks Range
1.28 - 1.43
4 Weeks Price Volatility (%)
60.00%
52 Weeks Range
1.07 - 1.46
52 Weeks Price Volatility (%)
76.92%
Previous Close
1.39
Open
1.40
Bid
1.36 x 102,800
Ask
1.38 x 31,300
Day's Range
1.36 - 1.40
Trading Volume
396,600
Financial Highlight
Latest Quarter | Ann. Date
31-Mar-2025 [#1] | 15-May-2025
Next QR | Est. Ann. Date
30-Jun-2025 | 15-Aug-2025
T4Q P/E | EY
18.02 | 5.55%
T4Q DY | Payout %
2.19% | 39.49%
T4Q NAPS | P/NAPS
0.74 | 1.85
T4Q NP Margin | ROE
8.26% | 10.27%
Market Buzz
2025-07-08
2025-07-03
2025-07-01
2025-07-01
2025-06-30
News and Blogs
Related videos
Company Profile
Sector: HEALTH CARE
Sector: HEALTH CARE
Subsector: PHARMACEUTICALS
Subsector: PHARMACEUTICALS
Description:
Duopharma Biotech Berhad, an investment holding company, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia. The company provides products in various forms, including tablets, capsules, syrups, oral antibiotics, creams, hemodialysis solutions, sterile irrigation solutions, sterile powder and small volume injectable forms, dental cartridges, and eye drop preparations. It offers generic and halal pharmaceutical products; and over-the-counter products primarily under the Champs, Flavettes, Proviton, Naturalle, Uphamol, Eye Glo, Donna, and Alucid brands, as well as analgesics, antihistamines, etc. The company also operates under the OMESEC brand name. In addition, it is also involved in the property management activities; and distribution of chemical products. Duopharma Biotech Berhad also exports its products to Vietnam, Ethiopia, Sudan, Southeast Asia, Papua New Guinea, Pakistan, Bangladesh, Sri Lanka, the Republic of Yemen, Singapore, and Hong Kong. The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019. The company was founded in 1979 and is based in Klang, Malaysia. Duopharma Biotech Berhad is a subsidiary of Permodalan Nasional Berhad.
Discussions
13 people like this. Showing 50 of 12,448 comments
This is just reaction to Covid case spike, after that fall back down. Nothing new and exciting on the horizon for pharma in the coming months especially when Pharmaniaga still in the dump and government cutting back on spending.
2023-12-15 16:03
Hope this collaboration can bring good revenue to the company for Fy2024 and so on
https://theedgemalaysia.com/node/692365
2024-01-15 17:14
Duopharma Biotech Bhd is likely to see a recovery in its consumer healthcare (CHC) segment, while sales to the government sector is also expected to increase in 2024.
https://www.thestar.com.my/business/business-news/2024/01/26/duopharma-earnings-set-to-improve-this-year
2024-01-30 17:36
Duopharma Biotech Clinches MYR578 million Supply Deals
https://www.tradingview.com/news/mtnewswires.com:20240501:G2361746:0/
2024-05-02 09:21
Yuhoo!!! Finally Duo making big move. 1.40 seems reasonable figure to relief breath.
2024-05-02 19:09
Ayo!!! What has 600m contract do to the Duo's share price??? Sometime the illogical happen.....
2024-05-04 18:39
Keep & follow TP from OSK
https://klse.i3investor.com/web/pricetarget/research/71461
2024-05-28 14:28
That is 1-year low price for Dpharma dude
fruitcake
1.10 please
19 hours ago
2024-06-14 11:03
Haha unfortunately i'm closing my position with Dpharma, feels like watching paint dry. Anyways good luck guys.
2024-06-26 11:32
I think they have. https://www.freemalaysiatoday.com/category/nation/2016/01/28/viagra-no-longer-hard-to-get/
2024-07-04 11:46
Duopharma Biotech 2Q net profit up 33%, pays one sen dividend 🔥
https://theedgemalaysia.com/node/722957
2024-08-16 11:40
DPHARMA: Reaping the Rewards of a Strong Ringgit
https://klse.i3investor.com/web/blog/detail/bestStocks/2024-09-26-story-h470048636-DPHARMA_Reaping_the_Rewards_of_a_Strong_Ringgit
2024-09-26 12:28
CGS International (CGSI) Research remains positive on Duopharma Biotech Bhd’s (DBB) earnings trajectory in financial year 2025 (FY25).
The research house said DBB’s earnings have been bottoming in FY23 and rebounding in FY24, and it projects the company to post further earnings growth with a three-year core earnings per share (EPS) compounded annual growth rate of 19.4% over FY24 to FY27.
“We expect earnings growth in FY25 to be driven by a full-year’s contribution from the approved products purchase list contracts secured in April last year, a stronger ringgit versus the US dollar, as well as lower application programming interface prices.
“Our minor adjustments to our revenue, depreciation and interest expense assumptions see our FY25 and FY26 forecasts core EPS estimates adjusted downwards by 1.1% and 0.2%,” the research house added.
CGSI Research said FY25 will be a year for DBB to optimise, execute, and plan for the future.
“With the manufacturing of most of its products now shifted from its K1 facility to its new K3 facility, DBB intends to further optimise its manufacturing processes in its facilities to cater to the growth in demand from the public healthcare space.
“Further, it is also evaluating and finalising plans to build further manufacturing capabilities in its K2 and K5 facilities.
“This plan is done with the intention to bring in products that could allow DBB to gain knowledge in developing and manufacturing biologicals, which we think could pave the way for stronger growth in the longer term,” it said.
Given that these plans would be firmed up in 2025, with most of the capital expenditure investments coming in 2026 onwards, the research house is maintaining the company’s dividend payout ratio at 38% between FY25 and FY27, providing yields of 3%.
That said, CGSI said it has not factored in the earnings upside from these in its forecasts.
DBB also believes that it can secure a similar contract value as its current insulin supply contract with the Health Ministry in the upcoming tender to be held in the second half of the year.
The Health Ministry needs more than one supplier and its partner Biocon’s Johor facility with the full drug manufacturing process provides more security in supply over Pharmaniaga Bhd’s new fill and finish facility, it noted.
The research house is retaining its “add” rating on the company with an unchanged Gordon growth model-based target price of RM1.55.
2025-03-27 09:15
Post a Comment
Featured Posts
Latest Videos
![[New IPO] Enproserve Group Berhad, a plant maintenance specialist in the O&G sector, plans to list on the Ace Market!](https://mqac.i3investor.com/img/video_thumbnail/1198/Thumbnail__(10).png)
![[New IPO] Icents Group Holdings Berhad, a specialised construction company focused on cleanroom EPCC services for industries, plans to list on the Ace Market!](https://mqac.i3investor.com/img/video_thumbnail/1192/Thumbnail__(9).png)
![[New IPO] A1 A.K. Koh Group Berhad, a well-established brand owner in the processed F&B industry, plans to list on the Ace Market!](https://mqac.i3investor.com/img/video_thumbnail/1186/Thumbnail__(8).png)
Apps
Top Articles
1
Koon Yew Yin's Blog
2
Stock Market Enthusiast
Winners and Losers from Bank Negara’s Surprise Rate Cut to 2.75%
3
4
PublicInvest Research
5
TA Sector Research
6
The Daily Pulse of Bursa Malaysia
7
THE INVESTMENT APPROACH OF CALVIN TAN
FIBER OPTIC - A VITAL CONNECTOR IN DATA CENTER & FOR WORLD WIDE CONNECTION AT SPEED OF LIGHT
8
PublicInvest Research
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
BobAxelrod33
Pharma is dying, yet this ctnr with Management in wheelchairs cannot take advantage.
2023-12-02 09:04